Six and eight weeks injection frequencies of bevacizumab are non-inferior to the current four weeks injection frequency for quality of life in neovascular age-related macular degeneration

A randomized controlled trial

Bibliographic Data

ID15296555
AuthorsMartijn S Visser (0000-0001-7022-7874, Erasmus MC, corresponding author), Sankha Amarakoon (0000-0002-9467-7519, Combined Ophthalmic Research Rotterdam), Tom Missotten (0000-0003-0600-9850, Combined Ophthalmic Research Rotterdam), Reinier Timman (0000-0002-7772-0394, Erasmus MC), Jan J V Busschbach (0000-0002-8602-0381, Erasmus MC)
Year2020
Volume29
Issue12
Pages3305-3313
Publication date2020-07-14
Open AccessYes
TypeARTICLE
VenueQuality of Life Research (JOURNAL)
Journal identifiersISSN: 0962-9343 • E-ISSN: 1573-2649
PublisherSpringer Science+Business Media (PUBLISHER • DE)
DOI10.1007/s11136-020-02580-9
PMID32666333
OpenAlexW3042473063
LanguageEN
References cited31

Non-inferiority of the 6 and 8 weeks frequencies was demonstrated compared to 4 weeks on vision-related and general QoL in patients with nARMD. These results are in line with previously published results of lower frequency injections regarding visual acuity and central retinal thickness. Lower injection frequency may reduce burden, side effects, and treatment costs. In consideration of these results, 8 weeks frequency injections of intravitreal bevacizumab could be considered in patients with nARMD

Bevacizumab · Chemotherapy · Macular degeneration · Quality of life (healthcare · Randomized controlled trial · Visual acuity · Medicine · Ophthalmology and Visual Impairment Studies · Retinal Diseases and Treatments · Retinal Imaging and Analysis · Ophthalmology · Surgery

Tools

Open DOIOpen Access